No Data
Volume change rate ranking (9 o'clock) ~ BASE, Kochi Bank, etc. ranked in.
※In the volume change rate ranking, by comparing the volume of the past 5 days on average with the volume on the distribution day, you can understand the interest of market participants such as trends in speculation. ■ Volume change rate top [As of 9:32 on November 7] (Comparison of past 5-day average volume) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <6177> AppBank 22,278 10 71 85.08% 3.74% <6518>
Slogan: Transcript of financial results briefing for the 2nd quarter of the fiscal year ending 2025/2
Stocks that moved the previous day part2: J-DEP ADVANCE, Kave, Metaplanet, etc.
Stock name <Code> Closing price on the 15th ⇒ Day-to-day comparison Bee With <9216> 1679 -139 Large decline in operating profit in the first quarter is viewed negatively. Osaka Organic Chemical Industry <4187> 3100 -1756 - Operating income decrease for August period expected to expand. Sansan <4443> 2166 -59 Limited positive impact on earnings. ENEOS <5020> 802.5 -39.7 Petroleum stocks are generally low due to the fall in crude oil prices. INPEX <1605> 2031.5 -68
Virginia Cancer Specialists Reveals New Brand Direction for Their Comprehensive Breast Center, Expansion of High-Risk Breast Clinic, and New Hope-Inspired Slogan in Honor of October, Breast Cancer Awareness Month
Stocks that moved the previous day part1 include Shochiku, AeroEdge, Koshidaka HD, etc.
Stock name <Code> 11th closing price ⇒ Previous day comparison Shochiku <9601> 9246 -106925 Financial estimates for the fiscal year ending February 25 have been revised downward. Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% in the previous period and 19.6% in this period. Part-time Thai <2341> 143 -8 The operating profit for the first half decreased by 98.2%, expanding the decrease rate from 80.3% in the first quarter. Chordia <190A> 296 -38 At the Japan Society of Hematology Academic Meeting, the first-phase clinical trial of the CLK inhibitor CTX-712.
Active and newly established stocks in the afternoon session.
*Matsushita <9601> 9246 -106 Lowered financial estimates for the fiscal year ending February 2025. *Vitz <4440> 840 +30 Operating profit expected to increase by 50.6% from the previous period and by 19.6% for the current period. *Albaitai <2341> 143 -8 The operating profit for the first half decreased by 98.2%, expanding the decrease rate from 80.3% in the first quarter. *Chordia <190A> 296 -38 Announcement of the results of the Phase I clinical trial of the CLK inhibitor CTX-712 at the Japan Society of Hematology Annual Meeting. *Aer